CGRP Treatments for Cluster Headache in 2026: What the New Evidence Says

This article is educational and is not medical advice. Cluster headache treatment decisions should be made with a qualified healthcare professional, especially if you are using prescription preventives, oxygen, triptans, high-dose vitamin D3, or more than one approach at the same time.

CGRP treatments have changed the migraine world, and they are now part of the cluster headache conversation too. In 2026, the evidence is more substantial than it was a few years ago, but it is still not simple. The clearest message is that CGRP-targeted drugs may help some people with cluster headache, especially episodic cluster headache, while the evidence in chronic cluster headache remains much less convincing.

That matters for anyone following the Vitamin D3 Anti-Inflammatory Regimen. CGRP treatments and the D3 regimen are not the same kind of intervention, and they should not be compared as if one study has settled the question. CGRP drugs are prescription biologic medicines tested in clinical trials. The D3 regimen is a patient-led nutritional and anti-inflammatory approach that should be monitored with blood tests. They occupy different places in the treatment discussion.

What is CGRP?

CGRP stands for calcitonin gene-related peptide. It is a neuropeptide involved in trigeminal pain signalling and blood-vessel biology. In cluster headache research, CGRP is important because attacks involve trigeminal-autonomic activation, CGRP can rise during attacks, and CGRP infusion can provoke attacks in susceptible people.¹

CGRP-targeted medicines include monoclonal antibodies that bind either the CGRP ligand or the CGRP receptor. Examples discussed in cluster headache research include galcanezumab, eptinezumab, fremanezumab, and erenumab. Some of these medicines are approved for migraine prevention. In the United States, galcanezumab is also indicated for the treatment of episodic cluster headache in adults.²

The 2026 review: promising, but not settled

The most useful recent summary is a 2026 systematic review and meta-analysis in BMC Neurology. The authors searched PubMed, Web of Science, Cochrane CENTRAL, ClinicalTrials.gov, and EBSCO for clinical trials of CGRP antagonists in adults with episodic or chronic cluster headache. They included four randomized controlled trials and two single-arm trials.³

Across the included studies, CGRP antagonists were associated with a mean reduction in weekly attacks of 7.23 attacks, with a 95% confidence interval from 4.60 to 9.86 fewer weekly attacks. The pooled >=50% responder rate was 46%, and the pooled >=30% responder rate was 59%.³

Those numbers sound encouraging, but they need context. The review combined different study designs, including single-arm trials, so the pooled reduction should not be read as a clean placebo-adjusted effect. The authors themselves concluded that the findings are supportive but less definitive, and that larger, longer-term, placebo-controlled randomized trials are still needed.³

Episodic cluster headache: galcanezumab has the strongest case

The best-known positive trial is the 2019 New England Journal of Medicine study of galcanezumab for episodic cluster headache. Adults received galcanezumab 300 mg monthly or placebo. Over weeks 1 to 3, weekly attacks fell by an average of 8.7 attacks in the galcanezumab group and 5.2 attacks in the placebo group. At week 3, 71% of patients in the galcanezumab group and 53% in the placebo group had at least a 50% reduction in weekly attack frequency.⁴

This is the reason galcanezumab is the CGRP drug most directly relevant to episodic cluster headache patients. The US prescribing information lists a recommended dose of 300 mg, given as three consecutive 100 mg subcutaneous injections at the onset of the cluster period, and then monthly until the end of the cluster period.²

It is still worth keeping expectations realistic. Episodic cluster headache naturally comes in bouts, and trial timing is difficult because some people improve as a bout starts to end. This makes cluster headache prevention trials harder to interpret than many people realise.

Chronic cluster headache: the evidence is more disappointing

Chronic cluster headache is where the CGRP story becomes much more cautious. A phase 3 trial of galcanezumab in chronic cluster headache did not show superiority over placebo for most endpoints.⁵

A 2025 randomized clinical trial of erenumab in chronic cluster headache was also negative. The authors concluded that blocking the CGRP receptor with erenumab was not successful for preventing attacks in that chronic cluster headache trial.⁶

Eptinezumab adds another mixed result. In a 2025 randomized trial in episodic cluster headache, eptinezumab did not significantly reduce attacks versus placebo on the primary endpoint, although some secondary measures and responder outcomes numerically favoured eptinezumab, and it was generally well tolerated.⁷

So the short version is this: the CGRP pathway clearly matters in cluster headache biology, but blocking CGRP does not produce the same strength of result across every drug, every trial design, or every cluster headache subtype.

A separate 2026 Cephalalgia systematic review focused on anti-CGRP monoclonal antibodies reached a similar cautious pattern: evidence looked more favourable in episodic cluster headache than chronic cluster headache, and interpretation was limited by variation in endpoints and study designs.⁸

Where does the Vitamin D3 Regimen fit?

The Vitamin D3 Regimen does not block CGRP directly. It is better thought of as a broader nutritional and anti-inflammatory strategy that many cluster headache patients have used alongside standard medical care. That is very different from a prescription biologic tested in a randomized trial.

That difference cuts both ways. CGRP drugs have formal trial evidence and regulatory review, but they may be expensive, access-limited, and not equally effective for episodic and chronic cluster headache. The D3 regimen is inexpensive and accessible, but it has not been tested against CGRP medicines in a head-to-head randomized trial. It should be discussed honestly, monitored properly, and not presented as a substitute for emergency or acute treatments. European Academy of Neurology guidelines strongly recommend 100% oxygen at a flow of at least 12 L/min for 15 minutes and 6 mg subcutaneous sumatriptan for acute cluster headache attacks, with verapamil recommended for prevention.⁹

There is also a research reason to keep vitamin D status in the discussion, without overstating it. A small 2018 preliminary study reported low 25(OH)D levels in a group of cluster headache patients, but the authors did not prove that vitamin D deficiency causes cluster headache or that correcting it prevents attacks.¹⁰

If you are using higher-dose vitamin D3, the safety conversation matters. The NIH Office of Dietary Supplements explains that vitamin D status is assessed with serum 25-hydroxyvitamin D, and that excessive vitamin D intake can cause high calcium levels and other toxicity concerns.¹¹ That is why this site keeps returning to 25(OH)D, calcium, PTH and kidney-function testing.

Practical questions to ask your doctor

• Do I have episodic or chronic cluster headache, and how does that affect CGRP treatment options?
• Is galcanezumab available or appropriate in my country for episodic cluster headache?
• What acute treatments should I have ready during an attack, such as oxygen or injectable/nasal triptans?
• If I am using the D3 regimen, what blood tests should we monitor and how often?
• Could any of my medications, kidney history, calcium results, or other conditions make high-dose vitamin D3 risky?

The takeaway

The 2026 CGRP evidence is encouraging but not final. Galcanezumab has the strongest specific evidence for episodic cluster headache, while chronic cluster headache trials have been more difficult and less positive. CGRP biology is clearly relevant, but CGRP medicines are not a universal answer.

For patients, the most sensible position is not "CGRP or D3." It is: use the best acute care available, discuss proven and emerging preventives with a clinician, and if you use the Vitamin D3 Regimen, do it with proper blood-test monitoring and clear safety boundaries.

References

1. Vollesen ALH, Snoer A, Beske RP, et al. Effect of infusion of calcitonin gene-related peptide on cluster headache attacks: a randomized clinical trial. JAMA Neurology. 2018;75(10):1187-1197. doi:10.1001/jamaneurol.2018.1675
2. US Food and Drug Administration. Emgality (galcanezumab-gnlm) prescribing information. Revised March 2025. FDA label PDF
3. Khanfar R, Radwan E, Hattab S. Safety and efficacy of calcitonin gene-related peptide antagonists for cluster headache: a systematic review and meta-analysis. BMC Neurology. 2026;26:195. doi:10.1186/s12883-026-04733-8
4. Goadsby PJ, Dodick DW, Leone M, et al. Trial of galcanezumab in prevention of episodic cluster headache. New England Journal of Medicine. 2019;381(2):132-141. doi:10.1056/NEJMoa1813440
5. Dodick DW, Goadsby PJ, Lucas C, et al. Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: results from 3-month double-blind treatment. Cephalalgia. 2020;40(9):935-948. doi:10.1177/0333102420905321
6. Mecklenburg J, Gaul C, Fitzek M, et al. Erenumab for chronic cluster headache: a randomized clinical trial. JAMA Network Open. 2025;8(6):e2516318. doi:10.1001/jamanetworkopen.2025.16318
7. Jensen RH, Tassorelli C, Tepper SJ, et al. Efficacy and safety of eptinezumab in episodic cluster headache: a randomized clinical trial. JAMA Neurology. 2025;82(7):706-714. doi:10.1001/jamaneurol.2025.1317
8. Kolakowski L, Kleinsorge MT, Wegener S, Pohl H. Efficacy and effectiveness of anti-CGRP monoclonal antibodies treatment in the prevention of cluster headache attacks: a systematic review and meta-analysis. Cephalalgia. 2026;46(4). doi:10.1177/03331024261434209
9. May A, Evers S, Goadsby PJ, et al. European Academy of Neurology guidelines on the treatment of cluster headache. European Journal of Neurology. 2023;30(10):2955-2979. doi:10.1111/ene.15956
10. Sohn JH, Chu MK, Park KY, Ahn HY, Cho SJ. Vitamin D deficiency in patients with cluster headache: a preliminary study. The Journal of Headache and Pain. 2018;19:54. doi:10.1186/s10194-018-0886-7
11. National Institutes of Health Office of Dietary Supplements. Vitamin D: Fact Sheet for Health Professionals. NIH ODS fact sheet